Pharma CEO medical affairs and key opinion leader delegation is a specialized leadership challenge in biopharmaceutical companies. Medical affairs serves as the scientific bridge between the pharmaceutical company and the medical community: educating healthcare providers on clinical evidence, engaging with academic thought leaders who influence clinical practice, supporting independent medical education, and managing relationships with key opinion leaders (KOLs) who shape physician perspectives on therapeutic areas.
These functions are regulated, technically complex, and require specialized expertise in both medicine and compliance. CEOs who remain personally involved in medical affairs decisions create governance confusion in a function that requires both scientific credibility and commercial independence. CEOs who delegate without appropriate governance risk compliance failures, inappropriate commercial influence on scientific communications, and missed opportunities to build the scientific reputation that differentiates pharmaceutical brands.
Medical Affairs as a Strategic Asset
Medical affairs has evolved from a regulatory and scientific support function into a strategic business capability. The medical affairs team builds the clinical evidence platform that supports payer reimbursement decisions, develops the physician education infrastructure that supports appropriate product utilization, and manages the KOL relationships that influence clinical guideline development and peer-to-peer education.
This strategic dimension requires a senior medical affairs leader with both scientific credibility and business judgment. The CEO should recruit and retain a Chief Medical Officer or VP of Medical Affairs who can own this function with genuine strategic authority.
Delegating to the Chief Medical Officer
The Chief Medical Officer (or VP Medical Affairs) should own the full medical affairs function: medical science liaison (MSL) management, KOL engagement programs, medical information services, health outcomes and real-world evidence programs, medical education strategy, and the scientific communications that support the product portfolio.
The CEO’s delegation to the CMO includes clear authority: the CMO makes medical affairs strategy decisions, manages the MSL field force, engages with KOLs and academic medical centers, and directs the medical education program within the compliance framework the company has established.
The CEO approves the medical affairs strategy and budget, engages with medical affairs in the context of pipeline strategy and launch preparation, and maintains relationships with the most significant scientific advisors and KOLs at the CEO-to-expert level for the company’s highest-priority therapeutic areas.
The Compliance Boundary
Medical affairs operates within a tightly regulated compliance framework. Interactions with healthcare providers, KOL engagement, and independent medical education are all subject to FDA guidance, OIG guidelines, and increasingly, state transparency requirements. The CEO must ensure the medical affairs function has robust compliance infrastructure, but should not manage compliance program operations.
The compliance function (often a separate Chief Compliance Officer or within the legal and regulatory team) provides independent oversight of medical affairs activities. The CEO receives compliance attestation from the CMO and compliance leadership, not through personal review of individual medical affairs activities.
The Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals establishes the ethical framework for pharmaceutical-healthcare provider interactions. The CEO’s role is to ensure the company’s practices comply with this framework; the CMO and compliance team own the operational compliance management.
Delegating KOL Management
Key opinion leader management is one of the most sensitive areas of medical affairs delegation. KOLs, scientific thought leaders who influence clinical practice through research, publications, speaking, and guideline participation, are valuable relationships for pharmaceutical companies in both medical and, within strict compliance boundaries, commercial dimensions.
The CMO and MSL team should own KOL relationship development and management for the full therapeutic area portfolio. This includes identifying appropriate KOL candidates, managing engagement within compliance parameters, coordinating advisory board participation, and coordinating speaking program involvement within the applicable regulations.
The CEO maintains relationships with a small number of the most senior scientific advisors, particularly those with whom the CEO has personal relationships from prior roles or who are engaged at the board or strategic advisory level. All other KOL relationships belong to the medical affairs organization.
Scientific Advisory Boards
Scientific advisory boards, which convene expert clinicians and researchers to advise on pipeline strategy and clinical development, require CEO-level engagement because they address strategic pipeline questions that the CEO must participate in. The CMO or VP of Clinical Development manages the advisory board operationally: agenda design, participant selection, compliance documentation, and follow-up.
The CEO participates in advisory board sessions as a strategic audience and decision-maker, not as a program manager.
For more on how medical affairs connects to the broader pharma CEO delegation structure, the pharma CEO regulatory affairs delegation guide provides context on aligning medical affairs with the regulatory strategy that shapes clinical programs.
Medical Science Liaison Management
The medical science liaison (MSL) field force provides scientific information and education to healthcare providers in the field. MSLs are advanced degree scientists or clinicians who build peer-level relationships with academic and community physicians, respond to unsolicited scientific inquiries, and gather field insights about scientific and clinical practice trends.
MSL management should be fully delegated to the VP of Medical Affairs and MSL management team: MSL hiring and training, territory management, performance evaluation, and the scientific training programs that keep MSLs current on the company’s clinical data.
The CEO reviews medical affairs field performance at the aggregate level: MSL productivity metrics, HCP engagement rates, and the field intelligence that medical affairs provides on competitive scientific activity. The CEO does not manage individual MSL performance or participate in field team management.
Conclusion
Pharma CEO medical affairs and KOL delegation is about building a scientific communications and engagement capability that advances the company’s pipeline visibility, supports appropriate product utilization, and maintains the scientific credibility that differentiates pharmaceutical brands in competitive therapeutic areas.
The pharma CEOs who build the most effective medical affairs functions invest in CMO leadership with both scientific credibility and business judgment, maintain robust compliance infrastructure, and govern medical affairs through strategy alignment and outcome metrics rather than operational involvement. The result is a medical affairs function that creates genuine scientific value for healthcare providers and patients while supporting the company’s commercial objectives within appropriate ethical boundaries. For more guidance, see our guide on pharma commercial delegation.
Related Reading
For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.